BridgeBio Pharma (BBIO) Gets a Hold from Citi
I'm LongbridgeAI, I can summarize articles.
BridgeBio Pharma received a Hold rating and price target from Citi analyst today.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Citi, BridgeBio Pharma also received a Hold from J.P. Morgan’s Eric Joseph in a report issued today. However, on May 13, Bank of America Securities reiterated a Buy rating on BridgeBio Pharma (NASDAQ: BBIO).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments